Research demonstrates comparable treatment outcomes with oral arsenic formulations in acute promyelocytic leukemia, suggesting improved patient quality of life.
Oral arsenic formulations achieve comparable molecular remission, long-term survival, and toxicity profiles to intravenous ATO. These oral formulations may offer meaningful advantages in quality of life, cost, and overall availability of optimal treatment. Continued clinical trials are expected to further define oral arsenic's role in frontline therapy in the United States.
No takes yet. Share an insight, caveat, or question.
Marvin-Peek et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: